Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Active, not recruiting · NCT05190445 · Registry updated 2022-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | HER2-positive Gastric Cancer | Active, not recruiting | Phase 2 | 2022-09-08 | NCT05190445 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Pieris Pharmaceuticals, Inc. | 1 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Maryland Oncology-Hematology | Silver Spring | United States | 1 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Samsung Medical Center | Seoul | South Korea | 170 |
| Sansum Clinic | Santa Barbara | United States | 20 |
| University of Texas MD Anderson Cancer Center | Houston | United States | 192 |